Zellsortiersystem

我们的工作重点是分析B细胞和抗体对临床相关病原体（如HIV， HCV或埃博拉病毒）的反应。我们利用我们的发现来开发基于抗体的疗法，并为新的疫苗接种策略提供信息。在过去的几年里，我们已经能够识别出高度有效的抗体，我们也成功地在临床试验中进行了测试。我们先进的单细胞克隆方法主要依赖于多色流式细胞术和单细胞分选应用。有了这些方法，我们能够分离特定的细胞群，如幼稚或记忆B细胞，通过荧光染料标记它们。几个标签是产生纯B细胞亚群的必要条件，这反过来又需要一个带有几个激发激光器、发射滤波器和检测器的仪器。由于我们使用的是传染性材料（BSL2），因此仪器进一步需要在安全柜中操作。我们已经获得了进行这类实验的所有必要许可，但目前正在研究一种租赁仪器，租赁合同的期限是固定的。因此，我们申请了一个具有单细胞分选功能的流式细胞仪的资助，以继续我们对新的疫苗接种和治疗策略的深入研究。我们过去已经优化了我们的单细胞克隆方法，目前由于技术和结构的限制，达到了容量极限，这阻碍了我们正在进行和计划的项目的实现。基于我们在手工单细胞克隆方面的经验，我们计划建立一个自动化的单细胞抗体分析和筛选平台。有了这个，我们的目标是(i)增加样品吞吐量，（ii）通过减少体积来降低总成本，以及（iii）确保独立于任何实验者的所有分析的高质量。为此，我们申请资金用于液体处理机器人，该机器人能够并行处理384孔板格式的多个样品。自动化将使我们能够在更短的时间内识别针对现有和新出现的传染病的治疗适用抗体，从而加强我们作为卓越抗体分析中心的国内和国际地位。

Our work focuses on the analysis of B cell and antibody responses against clinically relevant pathogens such as HIV, HCV, or Ebola. We use our findings to develop antibody-based therapies and inform on novel vaccination strategies. In the last years, we have been able to identify highly potent antibodies that we also successfully tested in clinical trials. Our advanced single cell cloning methods critically rely on multicolor flow cytometry with bulk and single cell sorting applications. With these methods, we are able to isolate specific cell populations, such as naive or memory B cells, by labeling them with fluorescent dyes. Several labels are necessary to yield a pure B cell sub-population, which in turn requires an instrument with several excitation lasers, emission filters, and detectors. Since we work with infectious materials (BSL2), the instrument further needs to be operated within a safety cabinet. We already have all necessary permissions to conduct these kind of experiments, but are currently working on a rental instrument with a fixed expiration of the rental contract. Thus, we apply for funding for a flow cytometer with single cell sorting function in order to continue our intensive research on novel vaccination- and therapy strategies.We have optimized our single cell cloning methods in the past and currently reached a capacity limit due to technical and structural limitations, which hampers the realization of our ongoing and planed projects. Based on our experience in manual single cell cloning, we plan to build an automated single cell platform for antibody analysis and screening. With this, we aim to (i) increase the sample throughput, (ii) reduce overall costs by volume reduction, and (iii) ensure a high quality among all analyses independent of any experimenter. To this end, we apply for funding for a liquid handling robot, that is able to process several sample in a 384-well plate format in parallel. The automation will allow us to identify therapeutically applicable antibodies against established and emerging infectious diseases in a shorter time frame and thereby strengthen our national and international position as an antibody analysis center of excellence.